Alitair receives U.S. Patent allowance for ion exchange resin formulation of benzonatate Alitair Pharmaceuticals, Inc., today announced that it received a Notice of Allowance from america Patent and Trademark Workplace because of its ion exchange resin formulation of benzonatate. The patent includes specific statements for eliminating or reducing the choking hazard associated with standard liquid formulations of benzonatate. Our oral solid ion exchange resin formulation provides been proven to reduce or get rid of the choking hazard, stated Alitair CEO and President, William W.Key Findings Programs increased the level and changed the content of health, family existence, and sex education. Applications also increased participants’ perceived value of the services. For example, program youth were significantly more likely than their control group counterparts to survey that the classes or applications they attended had elevated their knowledge of being pregnant and sexually transmitted illnesses. Program youth were more likely to pledge abstinence.